Beryl Drugs Ltd

Beryl Drugs Ltd

Beryl Drugs Ltd has filed reports for the quarter ended 30.09.2026, including a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, and a non-applicability certificate under Regulation 57(5).

Beryl Drugs Ltd

Beryl Drugs Ltd has filed a non-applicability certificate under Regulation 57(5) for the quarter ended 30.09.2026, stating that there are no non-convertible securities for which interest/dividend/principal is payable during the quarter.

Beryl Drugs Ltd

Beryl Drugs Ltd has announced the closure of its trading window for all board members, promoters, and connected persons from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ended September 30, 2026.

Beryl Drugs Ltd

Beryl Drugs Ltd has announced the voting results of its 33rd Annual General Meeting (AGM) held on September 29, 2026. The company has provided the Scrutinizer's Report, which details the voting results for the resolutions passed at the AGM.

Beryl Drugs Ltd

Beryl Drugs Ltd held its 33rd Annual General Meeting on September 29, 2026, at Kanchan Palace, Community Hall, Nipania Ring Road, Indore. The meeting was chaired by Mr. Sudhir Sethi, and 47 members attended. The agenda included adopting the audited standalone financial statements for the year ended March 31, 2026, and approving the increase in the limit of material related party transactions with m/s. Aminova Infusions. The resolutions were passed by ordinary resolutions.

Beryl Drugs Ltd

Beryl Drugs Ltd has approved an increase in the limit of material related party transactions with M/S. Aminova Infusions Pvt. Ltd. from ₹5.00 crore to ₹8.00 crore.

Beryl Drugs Ltd

Beryl Drugs Ltd has announced the outcome of its 33rd Annual General Meeting, where the company adopted its audited financial statements for FY 2025-26, reappointed a director, and approved an increase in material related party transactions with Aminova Infusions Pvt. Ltd.

Beryl Drugs Ltd

Beryl Drugs Ltd has announced the publication of its 33rd Annual General Meeting (AGM) notice in a newspaper, with the AGM scheduled to be held on September 26, 2026, through video conferencing.

Beryl Drugs Ltd

Beryl Drugs Ltd has announced its 33rd Annual Report for the financial year 2025-2026, which includes the audited standalone financial statements, reports of the Board of Directors and Auditors, and notice of the 33rd Annual General Meeting.

Beryl Drugs Ltd

Beryl Drugs Ltd has announced its 33rd Annual General Meeting (AGM) to be held on September 29, 2026, at Kanchan Palace, Indore. The meeting will consider the audited standalone financial statements for the year ended March 31, 2026, and re-appointment of Mr. Sudhir Sethi as a director. Additionally, the meeting will consider an increase in the limit of material related party transactions with Aminova Infusions Pvt. Ltd.

Beryl Drugs Ltd

Beryl Drugs Ltd has announced the e-voting dates for its 33rd Annual General Meeting to be held on September 29, 2026. The e-voting facility will be available from September 26, 2026, to September 28, 2026.

Beryl Drugs Ltd

Beryl Drugs Ltd has announced the record date for its 33rd Annual General Meeting, to be held on September 29, 2026. The company has fixed September 22, 2026, as the cut-off date for determining the entitlement of voting rights for remote e-voting.

Beryl Drugs Ltd

Beryl Drugs Ltd held its 5/2026-2027 Board Meeting on September 2, 2026, and approved several matters, including the Board report, notice of the 33rd Annual General Meeting, and increase in the limit of material related party transactions with Aminova Infusions Pvt. Ltd.

Beryl Drugs Ltd

Beryl Drugs Ltd has scheduled a Board Meeting on 02/09/2026 to consider and approve the Board report and other matters related to the 33rd Annual General Meeting of the Company.

Beryl Drugs Ltd

Beryl Drugs Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, related to Sudhir Sethi's substantial acquisition of shares.

Beryl Drugs Ltd

Beryl Drugs Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, related to Sudhir Sethi's acquisition of shares.

Beryl Drugs Ltd

Beryl Drugs Ltd has published its unaudited quarterly financial results for the quarter ended 30th June, 2026, in the newspapers as required by SEBI regulations.

Beryl Drugs Ltd

Beryl Drugs Ltd has announced unaudited financial results for the quarter ended 30th June, 2026. The company reported a net profit of ₹22.08 crore, with earnings per share (EPS) of ₹0.47. The results were prepared in accordance with Indian accounting principles and were reviewed by the statutory auditors.

Beryl Drugs Ltd

Beryl Drugs Ltd has announced the outcome of its board meeting, where it considered and approved the unaudited financial results for the quarter ended June 30, 2026, and took on record the limited review report by the auditors.

Beryl Drugs Ltd

Beryl Drugs Ltd has scheduled a board meeting on 11/08/2026 to consider and approve the unaudited financial results for the quarter ended 30th June, 2026.